Please assess the completion status of the following clinical trial:

Trial Title: Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject and the parent/guardian of the subject, was to have demonstrated their willingness to participate in the study and comply with its procedures by signing a written Informed Consent~* 6-11 years old, either sex, either race~* If female, subject to be premenarcheal~* Willing to avoid eating, drinking, gum chewing, and teeth brushing for one hour prior to enrollment.~* Free of any clinically significant disease that would interfere with study evaluations, including allergic rhinitis and respiratory infections.~* Able to adhere to the dosing and visit schedules~Exclusion Criteria:~* If female, subject who was pregnant, intended to become pregnant during the study or nursing.~* Subject had used any investigational product within 30 days prior to enrollment.~* Subject had any of the following clinical conditions: history of any significant medical conditions (based on reporting by parent or guardian): e.g., diabetes, heart disease, liver disease, kidney disease, breathing problems, cough with excessive phlegm, or persistent or chronic cough.~* Subject had a current medical condition that, in the opinion of the Investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, allergic rhinitis, etc.).~* Subject was participating in any other clinical study(ies).~* Subject was part of the staff or a family member of the staff personnel directly involved with this study.~* Subject was allergic to or has sensitivity to the study drug or its excipients.~* Subject had a history of allergic reaction to prescription and/or over the counter (OTC) medications and/or food products.~* Subject had used any antihistamines within 24 hours prior to tasting as outlined in Section 9.4.7.~* Subject used sedatives, tranquilizers, or monoamine oxidase inhibitor drugs.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- RediTab/Zyrtec (Type: ACTIVE_COMPARATOR): Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
- Zyrtec/RediTab (Type: ACTIVE_COMPARATOR): Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).